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o Institut Gustave Roussy, Université Paris-Saclay, Villejuif, FranceReceived 19 February 2021; received in revised form 26 May 2021; accepted 3 June 2021




prostate cancer* Corresponding author: Genitourinar
Boston, MA, 02114, USA.
E-mail address: smith.matthew@mg
https://doi.org/10.1016/j.ejca.2021.06.01
0959-8049/ª 2021 The Authors. Publish
licenses/by/4.0/).Abstract Background: In the ARAMIS trial, darolutamide plus androgen deprivation ther-
apy (ADT) versus placebo plus ADT significantly improved metastasis-free survival (MFS),
overall survival (OS) and time to pain progression in patients with non-metastatic castra-
tion-resistant prostate cancer (nmCRPC). Herein, we present analyses of patient-reported
health-related quality of life (HRQoL) outcomes.y Malignancies Program, Massachusetts General Hospital Cancer Center, Yawkey 7030, 55 Fruit Street
h.harvard.edu (M.R. Smith).
0
ed by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/





erelated symptomsPatients and methods: This double-blind, placebo-controlled, phase III trial randomised pa-
tients with nmCRPC and prostate-specific antigen doubling time 10 months to darolutamide
600 mg (n Z 955) twice daily or matched placebo (n Z 554) while continuing ADT. The pri-
mary end-point was MFS; the secondary end-points included OS and time to pain progres-
sion. In this analysis, HRQoL was assessed by the time to deterioration using the
Functional Assessment of Cancer TherapyeProstate (FACT-P) prostate cancer subscale
(PCS) and the European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire Prostate Cancer Module (EORTC QLQ-PR25) subscales.
Results: Darolutamide significantly prolonged time to deterioration of FACT-P PCS versus
placebo (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.70e0.91; P Z 0.0005) at
the primary analysis (cut-off date: 3rd September 2018). Time to deterioration of EORTC
QLQ-PR25 outcomes showed statistically significant delays with darolutamide versus placebo
for urinary (HR 0.64, 95% CI 0.54e0.76; P < 0.0001) and bowel (HR 0.78, 95% CI 0.66e0.92;
P Z 0.0027) symptoms. Time to worsening of hormonal treatmenterelated symptoms was
similar between the two groups.
Conclusion: In patients with nmCRPC who are generally asymptomatic, darolutamide main-
tained HRQoL by significantly delaying time to deterioration of prostate cancerespecific
quality of life and disease-related symptoms versus placebo.
ª 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Prostate cancer is the second most common malig-
nancy in men and is a leading cause of mortality. In
2018, there were more than 360,000 deaths
from prostate cancer in men worldwide [1]. Androgen
deprivation therapy (ADT) is part of the standard of
care for patients whose prostate cancer recurs after
primary treatment. Although nearly all patients
initially respond to ADT, most eventually develop
castration-resistant prostate cancer (CRPC), defined as
rising levels of prostate-specific antigen (PSA) despite
continuous ADT [2]. CRPC in the absence of detect-
able metastases on conventional imaging is classified as
non-metastatic CRPC (nmCRPC). Most patients with
nmCRPC will progress to metastatic CRPC, which is
associated with significantly reduced overall survival
(OS). Patients with nmCRPC are generally older (me-
dian age 73 years in the SPARTAN and PROSPER
trials), are asymptomatic and, compared with those
with more advanced disease, tend to have reasonable
health-related quality of life (HRQoL) [3e5]. There-
fore, understanding the impact of treatment on QoL is
clinically important.
Darolutamide is an oral androgen receptor inhibitor
(ARI) approved for the treatment of nmCRPC, after
demonstrating significantly prolonged metastasis-free
survival (MFS) compared with placebo (median 40.4
months versus 18.4 months, hazard ratio [HR] 0.41, 95%
confidence interval [CI] 0.34e0.50; P < 0.001) in the
primary analysis of the phase III ARAMIS trial (data
cut-off 3rd September 2018) [6]. Darolutamide also
significantly improved OS (HR 0.69; 95% CI 0.53e0.88;
P Z 0.003) compared with placebo at the final analysis(data cut-off 15th November 2019) [7]. In addition, time
to pain progression significantly improved with dar-
olutamide versus placebo (HR 0.65, 95% CI 0.53e0.79;
P < 0.001) [7]. At both the primary and final analyses,
darolutamide demonstrated a favourable safety profile.
Most adverse events (AEs) commonly associated with
ARIs (e.g. fatigue, falls, mental impairment and hyper-
tension) showed 2% or less difference between dar-
olutamide and placebo groups; fatigue was the only AE
with a more than 10% incidence in the darolutamide
arm (13.2% versus 8.3% in the placebo arm) [6,7]. The
low risk of central nervous system AEs associated with
darolutamide may be due to the low bloodebrain bar-
rier penetration of darolutamide, as observed in non-
clinical models and functional neuroimaging studies in
humans [8,9]. Darolutamide also has a low potential for
drugedrug interactions with comedications commonly
taken for comorbid conditions by patients with
nmCRPC [10]. Furthermore, at primary analysis (data
cut-off 3rd September 2018), changes in HRQoL scores
over time compared with baseline favoured dar-
olutamide and showed statistically significant (but not
clinically relevant) changes compared with placebo [6].
In this analysis, we use data from the primary anal-
ysis of the ARAMIS trial to compare changes in patient-
reported HRQoL between darolutamide and placebo
using multiple validated questionnaires.
2. Methods
2.1. Study design and participants
The ARAMIS trial (NCT02200614) was a phase III,
randomised, double-blind, placebo-controlled trial
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Full details of the study have been previously reported
[6]. Briefly, eligible patients aged 18 years or older were
diagnosed with histologically or cytologically
confirmed adenocarcinoma of the prostate. Patients
were required to have a confirmed diagnosis of
nmCRPC, a baseline PSA level of at least 2 ng/ml, a
PSA doubling time (PSADT) of 10 months or less and
an Eastern Cooperative Oncology Group performance
status of 0 or 1. Patients were excluded if they had a
history of metastatic disease or distant metastases
detected by whole-body radionuclide bone scan and
computed tomography or magnetic resonance imaging
of the pelvis, abdomen and chest; the presence of pelvic
lymph nodes less than 2 cm in the short axis below the
aortic bifurcation was allowed. Prior seizure or con-
ditions predisposing to seizure were permitted. The
review board at each participating institution approved
the trial, which was conducted in compliance with the
principles of the Declaration of Helsinki and in
accordance with the International Conference on
Harmonisation Guidelines for Good Clinical Practice.
An independent Data and Safety Monitoring Board
reviewed unblinded safety data throughout the trial.
2.2. Randomisation and masking
At study initiation, patients were randomised 2:1 to oral
darolutamide (600 mg [two tablets of 300 mg] twice daily
with food) or matched placebo in a double-blind manner.
Patients continued treatment until protocol-defined pro-
gression, intolerable AEs or withdrawal of consent. Pa-
tients continued ADT (luteinising hormoneereleasing
hormone agonist or antagonist) throughout the trial.
Patients who initiated a prohibited therapy (detailed in
the study protocol, available online [6]) before confirma-
tion of metastasis were required to discontinue study
treatment and were followed for survival status. Ran-
domisation was stratified by PSADT (6 months versus
>6 months) and the use of osteoclast-targeted therapy at
randomisation (yes versus no).
2.3. Procedures
The impact of prostate cancer and treatment on
HRQoL was evaluated using the Functional Assess-
ment of Cancer TherapyeProstate (FACT-P) prostate
cancer subscale (PCS), assessed at screening, day 1,
week 16 and at every subsequent visit throughout the
double-blind period, until the end of treatment. The
PCS contains 12 questions scored on a Likert-type
scale from 0 to 4. Scores are combined for an overall
score ranging from 0 to 48, where higher scores
represent better QoL. The full 39-item FACT-P ques-
tionnaire (physical well-being, social and family well-being, emotional well-being and functional well-being
in addition to PCS) was also assessed at screening, day
1, week 16 and the end of treatment.
The impact of treatment on prostate cancererelated
QoL was evaluated using the European Organisation for
Research and Treatment of Cancer Quality of Life
Questionnaire Prostate Cancer Module (EORTC QLQ-
PR25), administered at screening, day 1, week 16 and
every 16 weeks until the end of treatment or death
throughout the double-blind period. The 25-item
EORTC QLQ-PR25 questionnaire assesses the effect of
urinary symptoms (8 items), bowel symptoms (4 items),
hormonal treatmenterelated symptoms (6 items), in-
continence aid use (1 item), sexual activity (2 items) and
sexual functioning (4 items). For the EORTC QLQ-
PR25, a higher functional score reflects better function
(for sexual activity and function), whereas higher
symptom scores reflect worsened symptoms. The
EORTC QLQ-PR25 utilises a 1e4 Likert-type scale to
answer items within a question format. These scores are
linearly converted and summated into a scaled score
from 0 to 100 [11].
2.4. Outcomes
The primary end-point in ARAMIS was MFS. The
secondary end-points included OS and time to pain
progression. QoL was an exploratory end-point. Here,
we report time to deterioration of FACT-P PCS and
EORTC QLQ-PR25 subscale scores.
2.5. Statistical analysis
The sample size was calculated based on the primary
end-point of MFS [6]. The full analysis set was used for
the HRQoL analysis reported herein, but it should be
noted that the trial was not specifically powered for
these HRQoL outcomes.
Time to deterioration for FACT-P PCS was defined
as a decline of 3 points in the PCS score from base-
line. Time to deterioration for EORTC QLQ-PR25
symptom subscales was defined as the first decline in
the HRQoL score from baseline equal to or greater
than the minimally important difference (MID, a
measure of clinical significance) defined as half the
standard deviation of the baseline value for each sub-
scale. Patients who did not report a decrease in
HRQoL equal to or greater than the MID were
censored at the date of their last visit. Time to deteri-
oration was analysed using a stratified log-rank test,
with the same stratification factors as for random-
isation; the HR and associated 95% CI were calculated
using a Cox proportional-hazards model. As multiple
comparisons were not accounted for, P values should
be interpreted as descriptive in nature.
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performed with SAS for Unix (SAS Institute Inc.,
Cary, NC, USA).3. Results
3.1. Patients
Between September 2014 and March 2018, 1509 patients
were randomly assigned in a 2:1 ratio (n Z 955 to the
darolutamide group, n Z 554 to the placebo group).
The clinical cut-off date for the analysis reported here
was 3rd September 2018. The median follow-up time
was 17.9 months. Median treatment duration was
14.8 months in the darolutamide group and 11.0 months
in the placebo group. Patient baseline and clinical char-
acteristics, including prior definitive treatment for pros-
tate cancer, were well balanced between treatmentTable 1
Patient demographics and clinical characteristics at baseline.
Characteristica Darolu
Median age (range), years 74 (48
Median serum PSA (range), ng/ml 9.0 (0.
PSA doubling time
Median (range), months 4.4 (0.
6 months, n (%) 667 (7
>6 months, n (%) 288 (3
ECOG performance status, n (%)
0 650 (6
1 305 (3
Use of bone-sparing agent, n (%)
Yes 31 (3)
No 924 (9
Prior treatment, n (%)





Active surveillance 12 (1)
Prior hormonal therapy,b n (%)
1 177 (1
2 727 (7
Not applicablec 51 (5)
FACT-P PCS score, mean (SD) [range] n Z 9
EORTC QLQ-PR25 score, mean (SD) [range]d
Bowel symptoms n Z 8
Hormonal treatmenterelated symptoms n Z 8
Incontinence aid use n Z 3
Sexual activity n Z 8
Sexual functioning n Z 1
Urinary symptoms n Z 8
ECOG, Eastern Cooperative Oncology Group; EORTC QLQ-PR25, Euro
Life Questionnaire Prostate Cancer Module; FACT-P, Functional Assess
ference; PCS, prostate cancer subscale; PSA, prostate-specific antigen; SD,
a Percentages may not total 100 because of rounding.
b Common prior hormonal therapies for prostate cancer (received by 
triptorelin (29%), bicalutamide (66%), flutamide (13%) and cyproterone (1
c Subjects who underwent surgical castration.
d The MID for bowel symptoms Z 4.91; hormonal treatmenterelated sym
sexual functioning Z 13.13; urinary symptoms Z 8.73.groups and have been reported previously [6]. Baseline
FACT-P PCS and EORTC QLQ-PR25 subscale scores
were at the high end of the scale in both treatment groups
(Table 1).3.2. Questionnaire completion
Patient compliance for completion of questionnaires
was assessed at each visit as the number of patients who
answered all questions out of the total number of pa-
tients to whom it was administered. The completion rate
for FACT-P PCS was 86% or higher in both groups,
aside from screening, day 1, week 16 and the end of
treatment when FACT-P PCS was collected as part of
the overall assessment of the full FACT-P questionnaire.
The compliance rate for completion of EORTC QLQ-
PR25 was 82% or higher in each group at all assessment



















49; 33 (6) [8e48] n Z 551; 33 (6) [10e47]
96; 6 (10) [0e56] n Z 511; 6 (10) [0e58]
96; 16 (13) [11e67] n Z 511; 17 (14) [17e61]
41; 12 (23) [0e100] n Z 180; 15 (26) [0e100]
88; 89 (19) [0e100] n Z 511; 90 (19) [0e100]
91; 44 (26) [0e100] n Z 118; 46 (26) [0e100]
95; 23 (17) [0e88] n Z 511; 24 (18) [0e100]
pean Organisation for Research and Treatment of Cancer Quality of
ment of Cancer TherapyeProstate; MID, minimally importance dif-
standard deviation.
10% of all patients) included leuprorelin (52%), goserelin (32%),
1%).
ptoms Z 6.68; incontinence aid use Z 12.15; sexual activity Z 9.59;
Table 2
EORTC QLQ-PR25 and FACT-P PCS completion rate.
Visit Darolutamide (n Z 955) Placebo (n Z 554) Total (n Z 1509)
EORTC QLQ-PR25, n/n (%)
Screening 773/955 (81) 436/554 (79) 1209/1509 (80)
Day 1 787/955 (82) 457/554 (83) 1244/1509 (82)
Week 16 766/913 (84) 445/516 (86) 1211/1429 (85)
Week 32 709/838 (85) 324/387 (84) 1033/1225 (84)
Week 48 583/684 (85) 232/283 (82) 815/967 (84)
Week 64 457/528 (87) 164/190 (86) 621/718 (86)
Week 80 349/393 (89) 106/124 (86) 455/517 (88)
Week 96 245/277 (88) 73/82 (88) 318/359 (88)
Week 112 176/206 (85) 46/55 (84) 222/261 (85)
Week 128 112/123 (90) 29/33 (88) 141/156 (90)
Week 144 65/73 (89) 13/15 (87) 78/88 (89)
Week 160 32/37 (87) 8/8 (100) 40/45 (89)
Week 176 16/19 (84) 1/1 (100) 17/20 (85)
Week 192 2/2 (100) 0 2/2 (100)
End of study treatment 164/229 (71) 208/288 (72) 372/517 (72)
FACT-P PCS,a n/n (%)
Screening 438/955 (46) 271/554 (49) 709/1509 (47)
Day 1 424/955 (44) 251/554 (45) 675/1509 (45)
Week 16 370/913 (41) 218/516 (42) 588/1429 (41)
Week 32 770/838 (92) 344/387 (89) 1114/1225 (91)
Week 48 635/684 (92) 250/283 (88) 885/967 (91)
Week 64 484/528 (92) 177/190 (93) 661/718 (92)
Week 80 366/393 (93) 111/124 (90) 477/517 (92)
Week 96 254/277 (91) 73/82 (88) 327/359 (91)
Week 112 188/206 (91) 47/55 (86) 235/261 (90)
Week 128 118/123 (95) 29/33 (88) 147/156 (94)
Week 144 71/73 (97) 15/15 (100) 86/88 (98)
Week 160 36/37 (97) 8/8 (100) 44/45 (98)
Week 176 19/19 (100) 1/1 (100) 20/20 (100)
Week 192 2/2 (100) 0 2/2 (100)
End of study treatment 64/229 (28) 100/288 (35) 164/517 (32)
EORTC QLQ-PR25, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Prostate Cancer Module;
FACT-P, Functional Assessment of Cancer TherapyeProstate; PCS, prostate cancer subscale.
a Patients were asked 12 questions (FACT-P PCS) with the exception of screening, day 1, week 16 and the end of treatment, when patients were
asked 39 questions (FACT-P PCS was collected in combination with overall FACT-P).
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(Table 2).
3.3. FACT-P PCS
This analysis assessed those patients who showed a
MID in scores from baseline. Darolutamide signifi-
cantly delayed time to deterioration of FACT-P PCS by
3.2 months more than placebo (darolutamide, median
11.1 months versus placebo, 7.9 months; HR 0.80, 95%
CI 0.70e0.91; P Z 0.0005; Fig. 1A).
3.4. EORTC QLQ-PR25
A post hoc analysis of time to deterioration in EORTC
QLQ-PR25 subscales showed statistically significant de-
lays in progression of urinary and bowel symptoms with
darolutamide versus placebo (Fig. 1B). Median time to
deterioration was 25.8 months versus 14.8 months
(treatment difference of 11 months; HR 0.64, 95% CI
0.54e0.76; P < 0.0001) for urinary symptoms and 18.4months versus 11.5 months (treatment difference of
6.9 months; HR 0.78, 95% CI 0.66e0.92; P Z 0.0027)
for bowel symptoms with darolutamide versus placebo,
respectively. There was no significant difference between
darolutamide and placebo in the time to deterioration of
hormonal treatmenterelated symptoms (breast tender-
ness, swelling in legs or ankles, hot flushes, problems
due to weight loss or gain and feelings of reduced
masculinity).
4. Discussion
In the ARAMIS trial of darolutamide plus ADT versus
placebo plus ADT, treatment with darolutamide signifi-
cantly delayed the time to worsening of prostate
cancererelated HRQoL, as measured by the FACT-P
PCS scores, thereby maintaining patients’ QoL for a
longer period than placebo. Urinary and bowel symp-
toms are the major contributing factors leading to dete-
rioration of QoL in patients with nmCRPC [12,13]. The
post hoc analysis of time to deterioration of EORTC
Fig. 1. Cox regression analysis of time to deterioration in FACT-P PCS scores (A) and EORTC QLQ-PR25 subscale scoresy (B). yThe
hazard ratio for sexual function was not significant because of the small numbers of patients who were sexually active: 100 in the dar-
olutamide group and 70 in the placebo group. CI, confidence interval; EORTC QLQ-PR25, European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire Prostate Cancer Module; FACT-P, Functional Assessment of Cancer Ther-
apyeProstate; NE, not estimable; PCS, prostate cancer subscale.
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significantly prolonged urinary symptom control by a
median of 11.0 months compared with placebo andbowel symptom control by 6.9 months. Many patients
with nmCRPC have cancer in the pelvic region, including
local recurrence within the prostate [14], that may
M.R. Smith et al. / European Journal of Cancer 154 (2021) 138e146144account for local symptom improvement associated with
darolutamide treatment. In addition, lower incidences of
urinary tract infection (4.9% versus 5.1%) and urinary
retention (3.5% versus 6.5%) were reported with dar-
olutamide versus placebo [6]. Adding androgen-targeted
therapy to ADT could negatively impact HRQoL
because of an increase in the number or severity of
symptoms associated with hormonal therapy [4]. How-
ever, in ARAMIS, no statistically significant differences
were observed in QoL due to hormonal treatmente
related symptoms between patients receiving dar-
olutamide and placebo. Given that patients with
nmCRPC are generally asymptomatic [5] and may
receive darolutamide treatment for prolonged periods of
time (median duration of darolutamide treatment was
14.8 months at the time of analysis), preventing deterio-
ration in HRQoL and treatment-induced morbidity is an
important clinical goal. Moreover, deterioration of
HRQoL in patients with recurrent prostate cancer,
including those with nmCRPC, as manifested by reduced
energy levels and/or physical and social dysfunction, may
result from advancing age of patients [15], the presence of
comorbidities and adverse effects of prior surgery, radi-
ation therapy and ongoing ADT [12,16]. As drugs that
delay disease progression of nmCRPC cannot mitigate
these factors, preventing deterioration of HRQoL is an
important clinical outcome of additional pharmaco-
therapy.
The HRQoL results from the ARAMIS trial are
consistent with those observed in the SPARTAN trial of
apalutamide and the PROSPER trial of enzalutamide,
both added to ongoing ADT in patients with nmCRPC.
Assessment of FACT-P demonstrated that HRQoL was
maintained over a substantial period with both apalu-
tamide (for approximately 25.8 months) and enzaluta-
mide (for 97 weeks [approximately 22 months]) [3,4].
However, assessment of HRQoL in ARAMIS,
SPARTAN and PROSPER may lack sensitivity. Given
that the three trials enrolled generally asymptomatic
patients with baseline HRQoL scores at the high end of
the assessed scale [3,4,6], this ‘ceiling effect’ limits the
ability to identify further improvement in HRQoL
during the specified duration of treatment. In addition,
potential disease-related deterioration in HRQoL may
not be apparent or manifested until several months after
metastasis and not within the follow-up time for
HRQoL assessments.
HRQoL analyses focussing on components specific
for prostate cancer may be more informative, as shown
for EORTC QLQ-PR25 in ARAMIS and PROSPER.
Both trials reported similar times to deterioration of
urinary and bowel symptoms that favoured dar-
olutamide and enzalutamide, respectively [4], which in
PROSPER was associated with disease control [17]. In
contrast, time to deterioration of hormonal
treatmenterelated symptoms was similar between
darolutamide and placebo in ARAMIS, but occurredmore quickly with enzalutamide versus placebo in
PROSPER [4], which may reflect the reported differ-
ences in the safety profiles of darolutamide and enza-
lutamide [6,18].
This study has several strengths. The large study
size and high questionnaire completion rates enabled
robust statistical analysis. The analyses focussed on
patients with a clinically significant change in QoL
and used assessment tools that were designed and
validated in prostate cancer. However, the results of
the study may have been affected by patient dropout.
The impact of treatment on HRQoL could have been
underestimated if patients who experienced a deteri-
oration in HRQoL were excluded from the study
analyses (174 [18%] of 955 darolutamide-treated pa-
tients and 163 [29%] of 554 placebo-treated patients
were lost to follow-up). The validity of the results
may also have been affected as HRQoL could have
differed between patients who completed the treat-
ment and those who discontinued participation and
failed to complete the assessments. In addition, the
study was not designed to evaluate local progression
of prostate cancer, limiting our ability to associate
deterioration of these patient-reported outcomes with
local or regional progression.
In conclusion, combined with the results in ARAMIS
of significantly increased MFS [6], OS [7] and time to
pain progression [7], these patient-reported outcomes
demonstrate that darolutamide significantly delayed the
time to deterioration of prostate cancerespecific QoL
and disease-related symptoms, compared with placebo,
in generally asymptomatic patients with nmCRPC.
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